aspirin has been researched along with telmisartan in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (43.33) | 29.6817 |
| 2010's | 16 (53.33) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bender, A; Czobor, P; Jelinek, B; Málnási-Csizmadia, A; Peragovics, Á; Simon, Z; Tombor, L; Végner, L | 1 |
| Bharate, SS; Vishwakarma, RA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Bellien, J; Bourkaib, R; Eltchaninoff, H; Iacob, M; Joannides, R; Thuillez, C | 1 |
| Diener, HC; Sacco, R; Yusuf, S | 2 |
| Diener, HC | 1 |
| Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S | 2 |
| Kent, DM; Thaler, DE | 1 |
| Kappelle, LJ | 1 |
| Gaikwad, AB; Mulay, SR; Tikoo, K | 1 |
| Bath, PM; Cotton, D; Diener, HC; Donnan, GA; Martin, RH; Ovbiagele, B; Vinisko, R; Yusuf, S | 1 |
| Blatchford, J; Demchuk, AM; Diehl, A; Diener, HC; Forsting, M; Gizewski, ER; Hermansson, K; Möller-Hartmann, C; Sacco, RL; Saver, JL; Wanke, I; Warach, S; Weber, R; Weimar, C | 2 |
| Guirguis-Blake, J | 1 |
| Kamal, AK; Wadiwala, MF | 1 |
| Duncton, MA; Singh, R | 1 |
3 review(s) available for aspirin and telmisartan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The PRoFESS trial: future impact on secondary stroke prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Forecasting; Humans; Internationality; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Telmisartan; Ticlopidine; Treatment Outcome; Vasodilator Agents | 2007 |
Adding ACE inhibitors or ARBs to standard therapy for stable ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Cough; Dizziness; Drug Therapy, Combination; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Patient Readmission; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Telmisartan | 2012 |
7 trial(s) available for aspirin and telmisartan
| Article | Year |
|---|---|
AT1 receptor blockade prevents the decrease in conduit artery flow-mediated dilatation during NOS inhibition in humans.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Aspirin; Benzimidazoles; Benzoates; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Endothelium, Vascular; Fluconazole; Humans; Male; Nitric Oxide Synthase; Nitroprusside; omega-N-Methylarginine; Radial Artery; Regional Blood Flow; Telmisartan; Vascular Resistance; Vasodilation; Vasodilator Agents | 2007 |
Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Double-Blind Method; Drug Combinations; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Research Design; Secondary Prevention; Stroke; Telmisartan; Ticlopidine; Treatment Outcome | 2007 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; Factor Analysis, Statistical; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk; Secondary Prevention; Stroke; Telmisartan; Ticlopidine; Vascular Diseases | 2008 |
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Cognition; Dipyridamole; Disability Evaluation; Double-Blind Method; Drug Administration Schedule; Drug Delivery Systems; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; International Cooperation; Male; Mental Status Schedule; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Secondary Prevention; Severity of Illness Index; Stroke; Telmisartan; Ticlopidine | 2008 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Cerebral Infarction; Clopidogrel; Dipyridamole; Female; Humans; Intracranial Embolism; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Secondary Prevention; Socioeconomic Factors; Stroke; Telmisartan; Ticlopidine; Tomography, X-Ray Computed; Treatment Outcome; Vasodilator Agents | 2012 |
Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS) MRI substudy.
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; Brain; Disease Progression; Female; Follow-Up Studies; Humans; Logistic Models; Magnetic Resonance Imaging; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Secondary Prevention; Stroke; Telmisartan; Treatment Outcome | 2012 |
What is better antiplatelet agent to prevent recurrent stroke?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopidogrel; Dipyridamole; Double-Blind Method; Evidence-Based Medicine; Humans; Male; Middle Aged; Patient Compliance; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Telmisartan; Ticlopidine; Treatment Outcome | 2012 |
20 other study(ies) available for aspirin and telmisartan
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
Topics: Algorithms; Angiotensin-Converting Enzyme Inhibitors; Animals; CHO Cells; Cricetulus; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Molecular Conformation; Molecular Targeted Therapy; Peptidyl-Dipeptidase A; Receptors, Dopamine D1; Receptors, Dopamine D2; Structure-Activity Relationship; Substrate Specificity | 2013 |
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
Topics: Drug Discovery; Pharmaceutical Preparations; Solubility; Thermodynamics | 2015 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
[Recurrence prophylaxis for stroke patients. Which platelet inhibitor combination protects best?].
Topics: Angiotensin II Type 1 Receptor Blockers; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimidazoles; Benzoates; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Humans; Middle Aged; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Telmisartan; Ticlopidine | 2003 |
[PRoFESS study presented. Change in secondary prevention].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimidazoles; Benzoates; Clopidogrel; Controlled Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Multicenter Studies as Topic; Placebos; Platelet Aggregation Inhibitors; Recurrence; Risk; Stroke; Telmisartan; Ticlopidine; Time Factors | 2003 |
Correction to the PRoFESS Trial paper by Diener et al. (Cerebrovasc Dis 2007;23:368-80.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimidazoles; Benzoates; Clopidogrel; Data Interpretation, Statistical; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Telmisartan; Ticlopidine | 2008 |
Stroke prevention--insights from incoherence.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk; Secondary Prevention; Stroke; Telmisartan; Ticlopidine | 2008 |
[Inhibition of platelet aggregation and angiotensin II-receptor blockade following TIA; the unexpected results of the Prevention Regimen For Effectively Avoiding Second Strokes (PROFESS) trial].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Headache; Humans; Platelet Aggregation Inhibitors; Stroke; Telmisartan; Ticlopidine | 2008 |
Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzimidazoles; Benzoates; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gene Expression Regulation; Inflammation; Male; NF-kappa B; Oxidative Stress; Rats; Rats, Sprague-Dawley; Signal Transduction; Smad Proteins; Streptozocin; Telmisartan; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2010 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; Brain Ischemia; Clopidogrel; Diastole; Dipyridamole; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Reference Values; Risk; Stroke; Systole; Telmisartan; Ticlopidine; Vascular Diseases | 2011 |
A one-pot synthesis of tetrazolones from acid chlorides: understanding functional group compatibility, and application to the late-stage functionalization of marketed drugs.
Topics: Aspirin; Azides; Benzimidazoles; Benzoates; Bexarotene; Carboxylic Acids; Chemistry Techniques, Synthetic; Chlorides; Indomethacin; Niacin; Probenecid; Silanes; Telmisartan; Tetrahydronaphthalenes; Tetrazoles | 2016 |